Iovance Biotherapeutics, Inc. specializes in individualized tumor infiltrating lymphocyte (TIL) cell therapies targeting solid tumors, with its main commercial product Amtagvi® approved for advanced melanoma. Historically, the company has operated at substantial losses driven by investment in clinical development and commercialization efforts, complicated by challenging manufacturing processes reliant on living cells and specialty materials. Despite regulatory approval milestones and market launches, Iovance continues to face headwinds related to operational scale-up, funding requirements, regulatory compliance, and competitive pressures within immuno-oncology. Monitoring cash flow trends and capital expenditure is critical given the absence of profitability to date.